{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T02:57:35Z","timestamp":1793156255794,"version":"4.5.0"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T00:00:00Z","timestamp":1727222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Drug infusion therapy after surgery for urothelial carcinoma is an effective measure to reduce cancer recurrence rate. Hydrogels are drug carriers with good biocompatibility and high drug loading capacity, which can optimize the pharmacokinetics of drugs in the urinary system to improve the therapeutic effect. Compared with the traditional free drug <jats:italic>in situ<\/jats:italic> perfusion, the hydrogel drug loading system can still maintain effective drug concentration in the face of continuous urinary flushing due to its good mucosal adhesion effect. The significantly prolonged drug retention time can not only improve the therapeutic effect of drugs, but also reduce the discomfort and risk of urinary tract infections caused by frequent drug infusion, and improve patient compliance. In addition, the combination of hydrogel with nanoparticles and magnetic materials can also improve the mucosal permeability and targeting effect of the hydrogel drug loading system, so as to overcome the mucus layer of urinary epithelium and the physiological barrier of tumor and minimize the impact on normal tissue and cell functions. At present, the research of hydrogels for urothelial cancer treatment involves chemotherapy, immunotherapy, gene therapy, inhibition of metabolism and multi strategy synergistic therapy. This review summarizes the research progress of hydrogels for the treatment of urothelial carcinoma, hoping to provide a reference for the future research of safe, reliable, effective, and advanced hydrogels with little side effects.<\/jats:p>","DOI":"10.3389\/fphar.2024.1478394","type":"journal-article","created":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T11:14:17Z","timestamp":1727262857000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Hydrogel-based formulations for urothelial cancer therapy"],"prefix":"10.3389","volume":"15","author":[{"given":"Mingyang","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changliang","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuozhu","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianing","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,9,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European association of urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur. Urol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","article-title":"Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study","volume":"22","author":"Balar","year":"2021","journal-title":"Lancet Oncol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1016\/S0140-6736(20)30415-3","article-title":"Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial","volume":"395","author":"Birtle","year":"2020","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1200\/JCO.20.01665","article-title":"Radical cystectomy against intravesical BCG for high-risk high-grade nonmuscle invasive bladder cancer: results from the randomized controlled BRAVO-feasibility study","volume":"39","author":"Catto","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1016\/S0140-6736(22)01188-6","article-title":"Current best practice for bladder cancer: a narrative review of diagnostics and treatments","volume":"400","author":"Comp\u00e9rat","year":"2022","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1152\/physrev.00041.2019","article-title":"The urothelium: life in a liquid environment","volume":"100","author":"Dalghi","year":"2020","journal-title":"Physiol. Rev."},{"key":"B8","doi-asserted-by":"publisher","first-page":"124957","DOI":"10.1016\/j.ijbiomac.2023.124957","article-title":"Mucoadhesive gellan gum-based and carboxymethyl cellulose -based hydrogels containing gemcitabine and papain for bladder cancer treatment","volume":"242","author":"de Lima","year":"2023","journal-title":"Int. J. Biol. Macromol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"587","DOI":"10.3390\/gels8090587","article-title":"Mucoadhesive polymers and their applications in drug delivery systems for the treatment of bladder cancer","volume":"8","author":"de Lima","year":"2022","journal-title":"Gels"},{"key":"B10","doi-asserted-by":"publisher","first-page":"737.e11","DOI":"10.1016\/j.urolonc.2020.05.002","article-title":"Intraoperative prophylactic intravesical chemotherapy to reduce bladder recurrence following radical nephroureterectomy","volume":"38","author":"Freifeld","year":"2020","journal-title":"Urol. Oncol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"105885","DOI":"10.1016\/j.ejps.2021.105885","article-title":"Optimization of a floating poloxamer 407-based hydrogel using the Box-Behnken design: in vitro characterization and in vivo buoyancy evaluation for intravesical instillation","volume":"163","author":"Goo","year":"2021","journal-title":"Eur. J. Pharm. Sci."},{"key":"B12","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.eururo.2018.09.047","article-title":"Extended versus limited lymph node dissection in bladder cancer patients undergoing radical cystectomy: survival results from a prospective, randomized trial","volume":"75","author":"Gschwend","year":"2019","journal-title":"Eur. Urol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.jconrel.2016.11.031","article-title":"Urothelium-adherent, ion-triggered liposome-in-gel system as a platform for intravesical drug delivery","volume":"245","author":"GuhaSarkar","year":"2017","journal-title":"J. Control Release"},{"key":"B14","first-page":"8970135","volume-title":"Synergistically enhanced mucoadhesive and penetrable polypeptide nanogel for efficient drug delivery to orthotopic bladder cancer","author":"Guo","year":"2020"},{"key":"B15","doi-asserted-by":"publisher","first-page":"7623","DOI":"10.2147\/IJN.S179226","article-title":"Enhanced photo\/chemo combination efficiency against bladder tumor by encapsulation of DOX and ZnPC into in situ-formed thermosensitive polymer hydrogel","volume":"13","author":"Huang","year":"2018","journal-title":"Int. J. Nanomedicine"},{"key":"B16","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.urolonc.2019.05.021","article-title":"The role of adjuvant radiotherapy after surgery for upper and lower urinary tract urothelial carcinoma: a systematic review","volume":"37","author":"Iwata","year":"2019","journal-title":"Urol. Oncol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e2206893","DOI":"10.1002\/advs.202206893","article-title":"Metabolic modulation of intracellular ammonia via intravesical instillation of nanoporter-encased hydrogel eradicates bladder carcinoma","volume":"10","author":"Jing","year":"2023","journal-title":"Adv. Sci. (Weinh)"},{"key":"B18","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/S1470-2045(20)30147-9","article-title":"Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, phase 3 trial","volume":"21","author":"Kleinmann","year":"2020","journal-title":"Lancet Oncol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.urology.2020.10.039","article-title":"Side effects of intravesical BCG and chemotherapy for bladder cancer: what they are and how to manage them","volume":"149","author":"Koch","year":"2021","journal-title":"Urology"},{"key":"B20","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.ijpharm.2017.08.120","article-title":"Advances in intravesical drug delivery systems to treat bladder cancer","volume":"532","author":"Kolawole","year":"2017","journal-title":"Int. J. Pharm."},{"key":"B21","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s00345-018-2606-y","article-title":"SIU-ICUD consultation on bladder cancer: treatment of muscle-invasive bladder cancer","volume":"37","author":"Leow","year":"2019","journal-title":"World J. Urol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.eururo.2020.07.003","article-title":"Neoadjuvant and adjuvant chemotherapy for upper tract urothelial carcinoma: a 2020 systematic review and meta-analysis, and future perspectives on systemic therapy","volume":"79","author":"Leow","year":"2021","journal-title":"Eur. Urol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.eururo.2018.12.028","article-title":"What is the standard of care for pelvic lymphadenectomy performed at the time of radical cystectomy?","volume":"75","author":"Lerner","year":"2019","journal-title":"Eur. Urol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.bioactmat.2020.08.019","article-title":"Self-crosslinkable chitosan-hyaluronic acid dialdehyde nanoparticles for CD44-targeted siRNA delivery to treat bladder cancer","volume":"6","author":"Liang","year":"2021","journal-title":"Bioact. Mater"},{"key":"B25","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.bioactmat.2023.08.013","article-title":"Intravesical chemotherapy synergize with an immune adjuvant by a thermo-sensitive hydrogel system for bladder cancer","volume":"31","author":"Liu","year":"2024","journal-title":"Bioact. Mater"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1021\/acsabm.8b00501","article-title":"Paclitaxel\/chitosan nanosupensions provide enhanced intravesical bladder cancer therapy with sustained and prolonged delivery of paclitaxel","volume":"1","author":"Liu","year":"2018","journal-title":"ACS Appl. Bio Mater"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e076743","DOI":"10.1136\/bmj-2023-076743","article-title":"Advances in diagnosis and treatment of bladder cancer","volume":"384","author":"Lopez-Beltran","year":"2024","journal-title":"Bmj"},{"key":"B28","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1097\/JU.0000000000002350","article-title":"Durability of response to primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel: OLYMPUS trial final report","volume":"207","author":"Matin","year":"2022","journal-title":"J. Urol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1001\/jama.2018.4657","article-title":"Effect of intravesical instillation of gemcitabine vs saline immediately following resection of suspected low-grade non-muscle-invasive bladder cancer on tumor recurrence: SWOG S0337 randomized clinical trial","volume":"319","author":"Messing","year":"2018","journal-title":"Jama"},{"key":"B30","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.euros.2021.09.013","article-title":"Intraoperative mitomycin C bladder instillation during radical nephroureterectomy is feasible and safe","volume":"34","author":"Nadler","year":"2021","journal-title":"Eur. Urol. Open Sci."},{"key":"B31","doi-asserted-by":"publisher","first-page":"10.e1","DOI":"10.1016\/j.urolonc.2021.05.014","article-title":"A feasibility study of preoperative pembrolizumab before radical nephroureterectomy in patients with high-risk, upper tract urothelial carcinoma: PURE-02","volume":"40","author":"Necchi","year":"2022","journal-title":"Urol. Oncol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.euf.2017.10.003","article-title":"Oncological outcomes of laparoscopic nephroureterectomy versus open radical nephroureterectomy for upper tract urothelial carcinoma: an European association of urology guidelines systematic review","volume":"5","author":"Peyronnet","year":"2019","journal-title":"Eur. Urol. Focus"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1007\/s00345-020-03474-8","article-title":"Immunotherapy in non-muscle-invasive bladder cancer: current status and future directions","volume":"39","author":"Pfail","year":"2021","journal-title":"World J. Urol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"52374","DOI":"10.1021\/acsami.1c14944","article-title":"Intravesical mucoadhesive hydrogel induces chemoresistant bladder cancer ferroptosis through delivering iron oxide nanoparticles in a three-tier strategy","volume":"13","author":"Qi","year":"2021","journal-title":"ACS Appl. Mater Interfaces"},{"key":"B35","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.tibtech.2019.12.012","article-title":"Intravesical hydrogels as drug reservoirs","volume":"38","author":"Qiu","year":"2020","journal-title":"Trends Biotechnol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1097\/JU.0000000000002454","article-title":"Antegrade instillation of UGN-101 (mitomycin for pyelocalyceal solution) for low-grade upper tract urothelial carcinoma: initial clinical experience","volume":"207","author":"Rosen","year":"2022","journal-title":"J. Urol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.eururo.2023.03.013","article-title":"European association of urology guidelines on upper urinary tract urothelial carcinoma: 2023 update","volume":"84","author":"Roupr\u00eat","year":"2023","journal-title":"Eur. Urol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/j.ijrobp.2021.03.001","article-title":"Long-term outcomes of radical radiation therapy with hypoxia modification with biomarker discovery for stratification: 10-year update of the BCON (bladder carbogen nicotinamide) phase 3 randomized trial (ISRCTN45938399)","volume":"110","author":"Song","year":"2021","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"B39","doi-asserted-by":"publisher","first-page":"958072","DOI":"10.3389\/fbioe.2022.958072","article-title":"Improvement of the bladder perfusion curative effect through tight junction protein degradation induced by magnetic temperature-sensitive hydrogels","volume":"10","author":"Sun","year":"2022","journal-title":"Front. Bioeng. Biotechnol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"B41","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.eururo.2015.05.050","article-title":"Systematic review and individual patient data meta-analysis of randomized trials comparing a single immediate instillation of chemotherapy after transurethral resection with transurethral resection alone in patients with stage pTa-pT1 urothelial carcinoma of the bladder: which patients benefit from the instillation?","volume":"69","author":"Sylvester","year":"2016","journal-title":"Eur. Urol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1007\/s00345-015-1753-7","article-title":"Early repeated ureteroscopy within 6-8 weeks after a primary endoscopic treatment in patients with upper tract urothelial cell carcinoma: preliminary findings","volume":"34","author":"Villa","year":"2016","journal-title":"World J. Urol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.1039\/d3tb02837b","article-title":"Hydrogel: a new material for intravesical drug delivery after bladder cancer surgery","volume":"12","author":"Wu","year":"2024","journal-title":"J. Mater Chem. B"},{"key":"B44","doi-asserted-by":"publisher","first-page":"6249","DOI":"10.2147\/IJN.S216432","article-title":"Intravesical delivery of rapamycin via folate-modified liposomes dispersed in thermo-reversible hydrogel","volume":"14","author":"Yoon","year":"2019","journal-title":"Int. J. Nanomedicine"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1080\/17425247.2020.1810016","article-title":"Current status of the development of intravesical drug delivery systems for the treatment of bladder cancer","volume":"17","author":"Yoon","year":"2020","journal-title":"Expert Opin. Drug Deliv."},{"key":"B46","doi-asserted-by":"publisher","first-page":"10258","DOI":"10.1016\/j.biomaterials.2013.09.027","article-title":"A magnetic chitosan hydrogel for sustained and prolonged delivery of Bacillus Calmette-Gu\u00e9rin in the treatment of bladder cancer","volume":"34","author":"Zhang","year":"2013","journal-title":"Biomaterials"},{"key":"B47","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jconrel.2023.01.001","article-title":"Mechanisms and strategies to enhance penetration during intravesical drug therapy for bladder cancer","volume":"354","author":"Zhang","year":"2023","journal-title":"J. Control. Release"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1478394\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T11:14:19Z","timestamp":1727262859000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1478394\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,25]]},"references-count":47,"alternative-id":["10.3389\/fphar.2024.1478394"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1478394","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,25]]},"article-number":"1478394"}}